Mitapivat sulfate(Pyrukynd)

被引：0

作者：

张冰 ^{[1
]}

王绍杰 ^{[1
]}

机构：

[1] 沈阳药科大学

来源：

中国药物化学杂志 | 2022年 / 32卷 / 10期

关键词：

D O I：

10.14142/j.cnki.cn21-1313/r.2022.10.009

中图分类号：

R977 [影响生长代谢机能药物];

学科分类号：

1007 ;

摘要：

2022年2月17日，Agios制药公司研发的丙酮酸激酶激活剂mitapivat sulfate经美国FDA批准上市，商品名为Pyrukynd，用于治疗丙酮酸激酶缺乏的成人溶血性贫血。丙酮酸激酶缺乏症是一种罕见的常染色体隐性遗传性疾病，表现为丙酮酸激酶活性降低，并出现慢性溶血性贫血，伴有无效红细胞生成的迹象。

引用

页码：818 / 818

页数：1

共 3 条

[1] Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias[J] . Al Samkari Hanny,van Beers Eduard J..Therapeutic Advances in Hematology . 2021
[2] The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model
Matte, Alessandro
Federti, Enrica
Kung, Charles
Kosinski, Penelope A.
Narayanaswamy, Rohini
Russo, Roberta
Federico, Giorgia
Carlomagno, Francesca
Desbats, Maria Andrea
Salviati, Leonardo
Leboeuf, Christophe
Valenti, Maria Teresa
Turrini, Francesco
Janin, Anne
Yu, Shaoxia
Beneduce, Elisabetta
Ronseaux, Sebastien
Iatcenko, Iana
Dang, Lenny
Ganz, Tomas
Jung, Chun-Ling
Iolascon, Achille
Brugnara, Carlo
De Franceschi, Lucia
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (10):
[3] Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
Grace, Rachael F.
Rose, Christian
Layton, D. Mark
Galacteros, Frederic
Barcellini, Wilma
Morton, D. Holmes
van Beers, Eduard J.
Yaish, Hassan
Ravindranath, Yaddanapudi
Kuo, Kevin H. M.
Sheth, Sujit
Kwiatkowski, Janet L.
Barbier, Ann J.
Bodie, Susan
Silver, Bruce
Hua, Lei
Kung, Charles
Hawkins, Peter
Jouvin, Marie-Helene
Bowden, Chris
Glader, Bertil
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (10): : 933 - 944

← 1 →